86 related articles for article (PubMed ID: 34282710)
1. A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy.
Filippi R; Montagnani F; Lombardi P; Fornaro L; Aprile G; Casadei-Gardini A; Faloppi L; Palloni A; Satolli MA; Scartozzi M; Citarella F; Lutrino SE; Vivaldi C; Silvestris N; Rovesti G; Rimini M; Aglietta M; Brandi G; Leone F
Acta Oncol; 2021 Oct; 60(10):1317-1324. PubMed ID: 34282710
[TBL] [Abstract][Full Text] [Related]
2. Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis.
Filippi R; Leone F; Fornaro L; Aprile G; Casadei-Gardini A; Silvestris N; Palloni A; Satolli MA; Scartozzi M; Russano M; Lutrino SE; Lombardi P; Frega G; Garattini SK; Vivaldi C; Spadi R; Giulia O; Fenocchio E; Brunetti O; Aglietta M; Brandi G
J Chemother; 2022 Apr; 34(2):123-132. PubMed ID: 34313188
[TBL] [Abstract][Full Text] [Related]
3. The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy.
Salati M; Caputo F; Cunningham D; Marcheselli L; Spallanzani A; Rimini M; Gelsomino F; Reggiani-Bonetti L; Andrikou K; Rovinelli F; Smyth E; Baratelli C; Kouvelakis K; Kalaitzaki R; Gillbanks A; Michalarea V; Cascinu S; Braconi C
Eur J Cancer; 2019 Aug; 117():84-90. PubMed ID: 31276980
[TBL] [Abstract][Full Text] [Related]
4. Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer.
Thol F; Gairing SJ; Czauderna C; Thomaidis T; Gamstätter T; Huber Y; Vollmar J; Lorenz J; Michel M; Bartsch F; Müller L; Kloeckner R; Galle PR; Wörns MA; Marquardt JU; Moehler M; Weinmann A; Foerster F
JHEP Rep; 2022 Mar; 4(3):100417. PubMed ID: 35141511
[TBL] [Abstract][Full Text] [Related]
5. Glasgow Prognostic Score predicts poor prognosis among advanced biliary tract cancer patients with good performance status.
Moriwaki T; Ishige K; Araki M; Yoshida S; Nishi M; Sato M; Yamada T; Yamamoto Y; Ozeki M; Ishida H; Yamaguchi T; Matsuda K; Murashita T; Abei M; Hyodo I
Med Oncol; 2014 Nov; 31(11):287. PubMed ID: 25316268
[TBL] [Abstract][Full Text] [Related]
6. Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study.
Walter T; Horgan AM; McNamara M; McKeever L; Min T; Hedley D; Serra S; Krzyzanowska MK; Chen E; Mackay H; Feld R; Moore M; Knox JJ
Eur J Cancer; 2013 Jan; 49(2):329-35. PubMed ID: 22947649
[TBL] [Abstract][Full Text] [Related]
7. Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer.
Fornaro L; Cereda S; Aprile G; Di Girolamo S; Santini D; Silvestris N; Lonardi S; Leone F; Milella M; Vivaldi C; Belli C; Bergamo F; Lutrino SE; Filippi R; Russano M; Vaccaro V; Brunetti AE; Rotella V; Falcone A; Barbera MA; Corbelli J; Fasola G; Aglietta M; Zagonel V; Reni M; Vasile E; Brandi G
Br J Cancer; 2014 Apr; 110(9):2165-9. PubMed ID: 24714745
[TBL] [Abstract][Full Text] [Related]
8. Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations.
Neuzillet C; Casadei Gardini A; Brieau B; Vivaldi C; Smolenschi C; Brandi G; Tougeron D; Filippi R; Vienot A; Silvestris N; Pointet AL; Lonardi S; Rousseau B; Scartozzi M; Dahan L; Aprile G; Boussaha T; Malka D; Crusz SM; Le Sourd S; Meurisse A; Lièvre A; Vernerey D; ; ; ;
Eur J Cancer; 2019 Apr; 111():94-106. PubMed ID: 30826661
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer.
McNamara MG; Templeton AJ; Maganti M; Walter T; Horgan AM; McKeever L; Min T; Amir E; Knox JJ
Eur J Cancer; 2014 Jun; 50(9):1581-9. PubMed ID: 24630393
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of preoperative inflammatory markers in resectable biliary tract cancer - Validation and comparison of the Glasgow Prognostic Score and Modified Glasgow Prognostic Score in a Western cohort.
Jansson H; Cornillet M; Björkström NK; Sturesson C; Sparrelid E
Eur J Surg Oncol; 2020 May; 46(5):804-810. PubMed ID: 31848078
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
Furuse J; Okusaka T; Ohkawa S; Nagase M; Funakoshi A; Boku N; Yamao K; Yamaguchi T; Sato T
Cancer Chemother Pharmacol; 2009 Dec; 65(1):113-20. PubMed ID: 19404641
[TBL] [Abstract][Full Text] [Related]
12. Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer.
Goktas Aydin S; Cakan Demirel B; Bilici A; Topcu A; Aykan MB; Kahraman S; Akbıyık I; Atci MM; Olmez OF; Yaren A; Sendur MAN; Geredeli C; Seker M; Urun Y; Karadurmus N; Aydin A
Curr Med Res Opin; 2022 Oct; 38(10):1751-1758. PubMed ID: 35916475
[TBL] [Abstract][Full Text] [Related]
13. Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer.
Neuzillet C; Casadei-Gardini A; Brieau B; Vivaldi C; Brandi G; Tougeron D; Filippi R; Vienot A; Silvestris N; Pointet AL; Lonardi S; Rousseau B; Scartozzi M; Dahan L; Aprile G; Le Sourd S; Evesque L; Meurisse A; Lièvre A; Vernerey D; ;
Int J Cancer; 2020 Dec; 147(11):3177-3188. PubMed ID: 32525595
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Factors for the Selection of Patients Eligible for Second-Line Chemotherapy in Advanced Biliary Tract Cancer.
Kang EJ; Choi YJ; Kim JS; Park KH; Oh SC; Seo JH; Kim HJ; Kang KW; Yu ES; Shin SW; Kim YH; Kim JS
Chemotherapy; 2014; 60(2):91-98. PubMed ID: 25720697
[TBL] [Abstract][Full Text] [Related]
15. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer.
Cho KM; Park H; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
Oncotarget; 2017 Jan; 8(2):2329-2341. PubMed ID: 27911876
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy.
Park I; Lee JL; Ryu MH; Kim TW; Sook Lee S; Hyun Park D; Soo Lee S; Wan Seo D; Koo Lee S; Kim MH
Cancer; 2009 Sep; 115(18):4148-55. PubMed ID: 19536892
[TBL] [Abstract][Full Text] [Related]
17. A Population-Based Retrospective Study of Biliary Tract Cancers in Alberta, Canada.
Beaulieu C; Lui A; Yusuf D; Abdelaziz Z; Randolph B; Batuyong E; Ghosh S; Bathe OF; Tam V; Spratlin JL
Curr Oncol; 2021 Jan; 28(1):417-427. PubMed ID: 33450805
[No Abstract] [Full Text] [Related]
18. Second-line chemotherapy in patients with advanced or recurrent biliary tract cancer: a single center, retrospective analysis of 294 cases.
Takahara N; Nakai Y; Isayama H; Sasaki T; Saito K; Oyama H; Kanai S; Suzuki T; Sato T; Hakuta R; Ishigaki K; Takeda T; Saito T; Mizuno S; Kogure H; Tada M; Koike K
Invest New Drugs; 2018 Dec; 36(6):1093-1102. PubMed ID: 30324343
[TBL] [Abstract][Full Text] [Related]
19. Systemic treatment in advanced biliary cancers: A multicenter Australian analysis and review.
Brungs D; Aghmesheh M; Sjoquist K; Goldstein D
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e291-e297. PubMed ID: 27860270
[TBL] [Abstract][Full Text] [Related]
20. CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer.
Takahara N; Nakai Y; Isayama H; Sasaki T; Saito K; Noguchi K; Suzuki T; Nakamura T; Sato T; Ishigaki K; Hakuta R; Takeda T; Uchino R; Mizuno S; Kogure H; Tada M; Koike K
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1105-1112. PubMed ID: 29038848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
